** Due to unforeseen circumstances, Dr. Bhisitkul will no longer be able to join the call. **

Please join us for the UNITY Biotechnology KOL webinar. The UNITY team will discuss its lead asset UBX1325, a potent Bcl-xL inhibitor, as a potential treatment solution to address the unmet medical need present in the age-related diseases of the eye. The discussion will highlight data on the impact of UBX1325 in patients with diabetic macular edema (DME).

The UNITY management team will also provide an update on upcoming data readouts from the ENVISION study in patients with wet AMD.

A live question and answer session will follow the formal presentation.